Europe
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
The technology also has intriguing potential in DNA forensics, even without the presence of other physical samples.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
It takes money to develop new, innovative treatments and this morning, multiple companies have announced significant fundraises. A summary of each financing round is below.
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
In mid-March, more than a dozen countries suspended the deployment of the AstraZeneca-Oxford University vaccine after incidences of blood clots were reported.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
PRESS RELEASES